Showing 541 - 560 results of 1,891 for search 'significantly ((((teer decrease) OR (greater decrease))) OR (larger decrease))', query time: 0.48s Refine Results
  1. 541
  2. 542
  3. 543
  4. 544
  5. 545
  6. 546
  7. 547
  8. 548
  9. 549
  10. 550

    Presentation 1_Ceftriaxone-associated dysbiosis decreases voriconazole bioavailability by upregulating intestinal P-glycoprotein expression through activation of the Nrf2-mediated... by Xiaokang Wang (733379)

    Published 2025
    “…</p>Key findings<p>The diversity and richness of intestinal bacteria, especially the abundance of gram-negative bacteria, were significantly decreased after ceftriaxone treatment. …”
  11. 551

    Table 1_Ceftriaxone-associated dysbiosis decreases voriconazole bioavailability by upregulating intestinal P-glycoprotein expression through activation of the Nrf2-mediated signall... by Xiaokang Wang (733379)

    Published 2025
    “…</p>Key findings<p>The diversity and richness of intestinal bacteria, especially the abundance of gram-negative bacteria, were significantly decreased after ceftriaxone treatment. …”
  12. 552

    Changes in best-corrected visual acuity and total area reduction ratio of the epiretinal membrane (ERM) during follow-up. by Su Hwan Park (15158181)

    Published 2025
    “…<p>(a) During the follow-up period, the stable group showed no significant change in visual acuity, whereas the progression group exhibited a decrease compared to baseline starting at 12 months, with greater changes than those in the stable group beginning at 6 months. …”
  13. 553

    Data. by Su Hwan Park (15158181)

    Published 2025
    “…Participants in the progression group were younger (60.7 vs. 65.7 years, P = 0.015) and showed a larger BCVA change (0.20 vs. 0.04, P < 0.001) and greater ERM area decrease (34.2% vs. 11.7%, P < 0.001) during the follow-up period. …”
  14. 554

    Baseline characteristics of patients. by Su Hwan Park (15158181)

    Published 2025
    “…Participants in the progression group were younger (60.7 vs. 65.7 years, P = 0.015) and showed a larger BCVA change (0.20 vs. 0.04, P < 0.001) and greater ERM area decrease (34.2% vs. 11.7%, P < 0.001) during the follow-up period. …”
  15. 555
  16. 556

    Advantages of Novel Anti-cancer Selenosemicarbazones: Preferential Reactivity of Their Fe(III), Cu(II), and Zn(II) Complexes with Key Physiological Reductants/Ligands Versus Isoste... by Mahendiran Dharmasivam (14165426)

    Published 2025
    “…The role of glutathione in all three latter reactions is significant, given the greater reactivity of the selenosemicarbazone, and glutathione’s key role in selenosemicarbazone and thiosemicarbazone anticancer activity.…”
  17. 557

    Advantages of Novel Anti-cancer Selenosemicarbazones: Preferential Reactivity of Their Fe(III), Cu(II), and Zn(II) Complexes with Key Physiological Reductants/Ligands Versus Isoste... by Mahendiran Dharmasivam (14165426)

    Published 2025
    “…The role of glutathione in all three latter reactions is significant, given the greater reactivity of the selenosemicarbazone, and glutathione’s key role in selenosemicarbazone and thiosemicarbazone anticancer activity.…”
  18. 558
  19. 559
  20. 560